Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Cyclooxygenase-2 negatively regulates innate lymphoid cell type 2 differentiation and function during allergic lung inflammation
Hong Li, Matthew L. Edin, Daniel Menendez, J. Alyce Bradbury, Joan P. Graves, Artiom Gruzdev, Gregory S. Whitehead, Maria I. Sifre, Laura M. DeGraff, Darryl C. Zeldin
Hong Li, Matthew L. Edin, Daniel Menendez, J. Alyce Bradbury, Joan P. Graves, Artiom Gruzdev, Gregory S. Whitehead, Maria I. Sifre, Laura M. DeGraff, Darryl C. Zeldin
View: Text | PDF
Research Article Immunology Pulmonology

Cyclooxygenase-2 negatively regulates innate lymphoid cell type 2 differentiation and function during allergic lung inflammation

  • Text
  • PDF
Abstract

Type 2 innate lymphoid cells (ILC2) are a population of lineage-negative cells in the lung, gastrointestinal tract, and skin that have emerged as a significant component of type 2 allergic inflammation. The regulation of cyclooxygenase-2 (COX-2) metabolites is critical to the pathophysiology of many inflammatory disorders, including allergic asthma. While COX-2 regulates Th9 and Th17 cell differentiation and function during allergic lung inflammation, it remains unknown whether COX-2 also regulates ILC2 cell differentiation and function under similar conditions. To address this question, we examined lung ILC2 cells from COX-2+/+ and COX-2–/– mice after ovalbumin-induced (OVA-induced) or Alternaria-induced allergic lung inflammation. ILC2 cells were significantly increased in COX-2–/– lungs compared with COX-2+/+ lungs after OVA exposure in vivo. The increase in ILC2 cells was accompanied by an increase in expression of the cytokines IL-5 and IL-13 and of the transcription factor GATA3. Both genetic disruption and selective inhibition of COX-2 significantly increased ILC2 cell differentiation from isolated common lymphoid progenitor cells (CLP) in vitro. Furthermore, COX-2–derived PGE2 acting via EP2 receptors significantly reduced IL-33 and TSLP expression, and it attenuated ILC2 cell differentiation in vitro and in vivo. Thus, during allergic lung inflammation, COX-2–derived PGE2 signals through the EP2 receptor to negatively regulate lung ILC2 cell differentiation and function.

Authors

Hong Li, Matthew L. Edin, Daniel Menendez, J. Alyce Bradbury, Joan P. Graves, Artiom Gruzdev, Gregory S. Whitehead, Maria I. Sifre, Laura M. DeGraff, Darryl C. Zeldin

×

Figure 7

COX-2 suppresses airway epithelial IL-33 and TSLP expression in vivo and in vitro.

Options: View larger image (or click on image) Download as PowerPoint
COX-2 suppresses airway epithelial IL-33 and TSLP expression in vivo and...
(A) After OVA-induced allergic inflammation, lung epithelial IL-33 and TSLP were visualized by confocal microscopy using anti-mouse antibodies to EpCAM (green), IL-33 or TSLP (red), and DAPI (blue), and the average pixel intensity in Epcam+ cells was quantified. Epithelial expression of both IL-33 and TSLP are increased in COX-2–/– mice relative to COX-2+/+ mice. (B and C) Levels of Il33 and Tslp mRNAs in lungs from OVA-treated (B), and PBS or Alternaria-treated (C), COX-2+/+ and COX-2–/– mice were measured by qPCR. (D) Purified COX-2–/– airway epithelial cells have increased levels of Il33 and Tslp after LPS treatment. In contrast, levels of Il25 remain unchanged. (E) PGE2 significantly inhibits Il33 and Tslp expression in purified airway epithelial cells from COX-2+/+ mice treated with LPS. n = 3–12 per group, *P < 0.05 by t test (A and B), multiple t tests (C and D) or 1-way ANOVA (E).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts